Washington—Organizers of a large breast cancer prevention study are calling on primary care physicians to be more active in finding candidates for the trial, called STAR (Study of Tamoxifen and Raloxifene), which is seeking 22 000 postmenopausal women in whom to compare the drugs tamoxifen (Nolvadex, Astra-Zeneca) and raloxifene (Evista, Eli Lilly & Co).
Vastag B. Breast Cancer Prevention Study Aims to Overcome Drug Bias. JAMA. 2001;285(4):399-400. doi:10.1001/jama.285.4.399-JMN0124-3-1